W C Stephen1, I Janssen. 1. School of Kinesiology and Health Studies, Queen's University, Kingston, Ontario, Canada.
Abstract
OBJECTIVES: To determine: 1) whether sarcopenic-obesity is a stronger predictor of cardiovascular disease (CVD) than either sarcopenia or obesity alone in the elderly, and 2) whether muscle mass or muscular strength is a stronger marker of CVD risk. DESIGN: Prospective cohort study. PARTICIPANTS: Participants included 3366 community-dwelling older (>or= 65 years) men and women who were free of CVD at baseline. MEASUREMENTS: Waist circumference (WC), bioimpedance analysis, and grip strength were used to measure abdominal obesity, whole-body muscle mass, and muscular strength, respectively. Subjects were classified as normal, sarcopenic, obese, or sarcopenic-obese based on measures of WC and either muscle mass or strength. Participants were followed for 8 years for CVD development and proportional hazard regression models were used to compare risk estimates for CVD in the four groups after adjusting for age, sex, race, income, smoking, alcohol, and cognitive status. RESULTS: Compared with the normal group, CVD risk was not significantly elevated within the obese, sarcopenic, or sarcopenic-obese groups as determined by WC and muscle mass. When determined by WC and muscle strength, CVD risk was not significantly increased in the sarcopenic or obese groups, but was increased by 23% (95% confidence interval: 0.99-1.54, P=0.06) within the sarcopenic-obese group. CONCLUSION: Sarcopenia and obesity alone were not sufficient to increase CVD risk. Sarcopenic-obesity, based on muscle strength but not muscle mass, was modestly associated with increased CVD risk. These findings imply that strength may be more important than muscle mass for CVD protection in old age.
OBJECTIVES: To determine: 1) whether sarcopenic-obesity is a stronger predictor of cardiovascular disease (CVD) than either sarcopenia or obesity alone in the elderly, and 2) whether muscle mass or muscular strength is a stronger marker of CVD risk. DESIGN: Prospective cohort study. PARTICIPANTS: Participants included 3366 community-dwelling older (>or= 65 years) men and women who were free of CVD at baseline. MEASUREMENTS: Waist circumference (WC), bioimpedance analysis, and grip strength were used to measure abdominal obesity, whole-body muscle mass, and muscular strength, respectively. Subjects were classified as normal, sarcopenic, obese, or sarcopenic-obese based on measures of WC and either muscle mass or strength. Participants were followed for 8 years for CVD development and proportional hazard regression models were used to compare risk estimates for CVD in the four groups after adjusting for age, sex, race, income, smoking, alcohol, and cognitive status. RESULTS: Compared with the normal group, CVD risk was not significantly elevated within the obese, sarcopenic, or sarcopenic-obese groups as determined by WC and muscle mass. When determined by WC and muscle strength, CVD risk was not significantly increased in the sarcopenic or obese groups, but was increased by 23% (95% confidence interval: 0.99-1.54, P=0.06) within the sarcopenic-obese group. CONCLUSION:Sarcopenia and obesity alone were not sufficient to increase CVD risk. Sarcopenic-obesity, based on muscle strength but not muscle mass, was modestly associated with increased CVD risk. These findings imply that strength may be more important than muscle mass for CVD protection in old age.
Authors: Marieke B Snijder; Ronald M A Henry; Marjolein Visser; Jacqueline M Dekker; Jacob C Seidell; Isabel Ferreira; Lex M Bouter; John S Yudkin; Nico Westerhof; Coen D A Stehouwer Journal: J Hypertens Date: 2004-12 Impact factor: 4.844
Authors: Radim Jurca; Michael J Lamonte; Carolyn E Barlow; James B Kampert; Timothy S Church; Steven N Blair Journal: Med Sci Sports Exerc Date: 2005-11 Impact factor: 5.411
Authors: M Visser; A B Newman; M C Nevitt; S B Kritchevsky; E B Stamm; B H Goodpaster; T B Harris Journal: Ann N Y Acad Sci Date: 2000-05 Impact factor: 5.691
Authors: Barbara J Nicklas; Brenda W J H Penninx; Matteo Cesari; Stephen B Kritchevsky; Anne B Newman; Alka M Kanaya; Marco Pahor; Ding Jingzhong; Tamara B Harris Journal: Am J Epidemiol Date: 2004-10-15 Impact factor: 4.897
Authors: B F Hurley; J M Hagberg; A P Goldberg; D R Seals; A A Ehsani; R E Brennan; J O Holloszy Journal: Med Sci Sports Exerc Date: 1988-04 Impact factor: 5.411
Authors: Fahad Javed; Emad F Aziz; Manpreet S Sabharwal; Girish N Nadkarni; Shahzeb A Khan; Juan P Cordova; Alexandre M Benjo; Dympna Gallagher; Eyal Herzog; Franz H Messerli; F Xavier Pi-Sunyer Journal: Obesity (Silver Spring) Date: 2010-12-23 Impact factor: 5.002
Authors: John E Morley; Angela Marie Abbatecola; Josep M Argiles; Vickie Baracos; Juergen Bauer; Shalender Bhasin; Tommy Cederholm; Andrew J Stewart Coats; Steven R Cummings; William J Evans; Kenneth Fearon; Luigi Ferrucci; Roger A Fielding; Jack M Guralnik; Tamara B Harris; Akio Inui; Kamyar Kalantar-Zadeh; Bridget-Anne Kirwan; Giovanni Mantovani; Maurizio Muscaritoli; Anne B Newman; Filippo Rossi-Fanelli; Giuseppe M C Rosano; Ronenn Roubenoff; Morris Schambelan; Gerald H Sokol; Thomas W Storer; Bruno Vellas; Stephan von Haehling; Shing-Shing Yeh; Stefan D Anker Journal: J Am Med Dir Assoc Date: 2011-07 Impact factor: 4.669
Authors: S J Baek; G E Nam; K D Han; S W Choi; S W Jung; A R Bok; Y H Kim; K S Lee; B D Han; D H Kim Journal: J Endocrinol Invest Date: 2014-01-09 Impact factor: 4.256
Authors: K Sanada; M Miyachi; M Tanimoto; K Yamamoto; H Murakami; S Okumura; Y Gando; K Suzuki; I Tabata; M Higuchi Journal: Eur J Appl Physiol Date: 2010-09 Impact factor: 3.078
Authors: Soo Lim; Jung Hee Kim; Ji Won Yoon; Seon Mee Kang; Sung Hee Choi; Young Joo Park; Ki Woong Kim; Jae Young Lim; Kyong Soo Park; Hak Chul Jang Journal: Diabetes Care Date: 2010-05-11 Impact factor: 19.112